|
Kevin B. Bacon, Ph.D.
Founder, CSO and Head of Research & Development
Dr. Bacon founded Actimis as a spin-off from Bayer
Yakuhin Ltd.’s Respiratory Research Department
in Kyoto, Japan. Dr. Bacon was most recently Vice President for
Respiratory diseases research with line and matrix management
responsibilities for respiratory small molecule therapeutic development
company-wide. Dr. Bacon was also involved in establishing and
managing major corporate collaborations and partnerships (Oxford
Glycosciences, Entelos, Lion, Galapagos Genomics, Inc., as well
as numerous academic and Institutional collaborations). Prior
to joining Bayer in 1999, Dr. Bacon was Associate Director of
Immunology at Neurocrine Biosciences, Inc., in San Diego, and
from 1994 to 1997 a Visiting Scientist at the DNAX Institute
for Molecular Biology (a subsidiary of Schering Plough), in Palo
Alto. Dr. Bacon received his B.Sc. and Ph.D. in Pharmacology
from the University of London (King’s College and United
Medical and Dental Schools of Guy’s and St. Thomas’,
respectively) and following post-doctoral studies, joined the
Glaxo Institute for Molecular Biology (now Serono) in Geneva,
Switzerland as a staff scientist focused on inflammation research.
Dr. Bacon has published over 100 original manuscripts, book chapters
and reviews and has been a regular contributor of original research
to the field of chemokine biology since its inception with specific
interest, and pioneering many studies, in the signaling mechanisms
of these molecules and their biological roles in cells of the
immune system.
Stefen A. Boehme, Ph.D.
Director of Immunology
Dr. Stefen Boehme joined Actimis in March 2005 as Director of Immunology,
and brings to Actimis 10 years of experience in drug development within the
pharmaceutical industry. Most recently, he conducted research at the La Jolla
Institute of Molecular Medicine focused upon inflammatory diseases such as
asthma. Prior to that, Dr. Boehme was a Senior Scientist at Genicon Sciences,
responsible for applying RLS (resonance light scattering) technology towards
facilitating the drug discovery cascade. From 1995 to 2003, Dr. Boehme held
numerous positions at Neurocrine Biosciences, where he was involved in developing
both small molecule and biological therapeutics for diseases such as asthma,
multiple sclerosis, type I diabetes and obesity. His post-doctoral training
was obtained at the National Institutes of Health in both the National Institute
of Allergy and Infectious Diseases and the National Cancer Institute. Dr. Boehme
received his B.S. from Muhlenberg College and a Ph.D. from the University of
Florida School of Medicine.
Tai Wei Ly, Ph.D.
Associate Director of Chemistry
Dr. Ly joined Actimis upon its inception and is Associate Director of Chemistry.
Most recently, he was a group leader in Bayer
Yakuhin Ltd.’s department of chemistry charged with the
management of chemistry support for early research projects in inflammation
and urology. Previous to that, Dr. Ly held the position of lab head and project
leader with responsibilities in the directing of chemistry activities for various
projects in the Respiratory Research Department. Dr. Ly received his B.Sc.
and Ph.D. in Chemistry from the University of Alberta in Canada and further
honed his skills in organic synthesis with a post-doctoral fellowship in the
Institute of Chemistry at Academia Sinica, Taiwan. Scientifically, Dr. Ly
is interested in the total synthesis of natural products and the development
of synthetic methodologies. Dr. Ly is the author of several peer-reviewed scientific
articles.
|
